RCKT News and Press, Rocket Pharmaceuticals Inc. From 09/13/23

2023-09-13 11:56:54 ET Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) were up by more than 36% as of 11 a.m. on Wednesday after the clinical-stage biotech company said late Tuesday that the Food and Drug Administration (FDA) had signed off on its phase 2 pivotal trial for a tre...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is one of today's top gainers. The company's shares are currently up 40.31% on the day to $21.45. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapi...

2023-09-13 10:18:38 ET DENVER, Colo., Sept 13, 2023 ( www.247marketnews.com)- News Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease AND Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock ...

2023-09-13 09:14:10 ET (24/7 MARKET NEWS) – Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stated, after yesterday’s market close, that it reached alignment with the Food and Drug Administration (FDA) on the global Phase 2 pivotal trial of RP-A501 for Danon Disease, a uniformly fa...

2023-09-13 07:59:44 ET More on Rocket Pharma Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earnings data for Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Therapy With ...

2023-09-13 06:12:47 ET More on Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts Biggest stock movers today: Rocket Pharmaceuticals and Granite Ridge Resources For fur...

2023-09-13 05:44:03 ET Related stories Granite Ridge Resources: Attempting To Scale Up Production Granite Ridge Resources, Inc. ( GRNT ) Q2 2023 Earnings Call Transcript Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts Granite Ridge R...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today the pricing of an underwritten public offering of (i) 7,...

2023-09-12 16:15:44 ET More on Rocket Pharmaceuticals Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earnings data for Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Ther...

2023-08-10 11:03:25 ET Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q2 GAAP EPS of -$0.82 in-line. Cash, cash equivalents and investments as of June 30, 2023, were $307.0 million. For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.82 in-line